Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share

Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• After-Hours Stock Movers: FDX, CBRS, NKE